

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65021

**Title:** Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers:  
State of art and an innovative approach for prevention

**Reviewer's code:** 05924759

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-02-26

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-03-15 09:09

**Reviewer performed review:** 2021-03-15 16:05

**Review time:** 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most life altering chemotherapy side effects. In this manuscript, Oneda et al summarized the evidence regarding the incidence of CIPN with different taxane formulations, regimen schedules and prevention systems. More importantly, based on their own experience, the authors introduced that the application of the Hilotherm® Chemo care device can effectively reduce the incidence of CIPN. This experience has certain guiding value in clinical practice. This also fully reflects the importance of nursing work. The article is well written and innovative.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65021

**Title:** Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers:  
State of art and an innovative approach for prevention

**Reviewer's code:** 05600796

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor, Surgical Oncologist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-02-26

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-03-15 15:14

**Reviewer performed review:** 2021-03-21 10:16

**Review time:** 5 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect that occurs in 20% of ovarian cancer patients treated with the combination of carboplatin and paclitaxel (CP). Multiple drugs have been used and studied for decades, their effect against CIPN are still controversial according to different antineoplastic agents due to the diverse manifestations among different antineoplastic agents and complex drug-drug interactions. So far, there is no agent recommended for the prevention of CIPN in guideline. The authors provide an innovative approach "Hilotherm® Chemo" for prevention of CIPN. I was particularly interested in this. However, for this manuscript, I was confused, if it is a review article why it has results and discussion part, and it may be better to discuss in each related section rather than make a separate discussion section. If it is an original article, please add a method section. There seem to be limited evidences to use Hilotherm® Chemo for prevention of CIPN. The author only shows two studies, one is a recent study in Germany, another for the author. However, the author provided a small retrospective study without a control group. The authors are required to provide more evidences to prove the efficiency, and discuss the weakness of Hilotherm® Chemo.